Get the Stockscreener App
57.63
0.02%
-0.010
After Hours:
57.63
Rapt Therapeutics Inc stock is traded at $57.63, with a volume of 1.93M.
It is down -0.02% in the last 24 hours and up +62.80% over the past month.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
See More
Previous Close:
$57.64
Open:
$57.65
24h Volume:
1.93M
Relative Volume:
1.82
Market Cap:
$1.67B
Revenue:
$3.25M
Net Income/Loss:
$-116.80M
P/E Ratio:
-18.90
EPS:
-3.05
Net Cash Flow:
$-98.17M
1W Performance:
+64.19%
1M Performance:
+62.80%
6M Performance:
+313.41%
1Y Performance:
+505.36%
1-Day Range:
$57.63
$57.67
1-Week Range:
$57.46
$57.70
52-Week Range:
$5.6652
$57.70
Rapt Therapeutics Inc Stock (RAPT) Company Profile
Name
Rapt Therapeutics Inc
Sector
Industry
Phone
(650) 489-9000
Address
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
Compare RAPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RAPT
Rapt Therapeutics Inc
|
57.63 | 1.67B | 3.25M | -116.80M | -98.17M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.41 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.55 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
814.74 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
357.98 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.32 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Initiated | Piper Sandler | Overweight |
| Oct-27-25 | Initiated | Guggenheim | Buy |
| Oct-20-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-13-25 | Initiated | Barclays | Overweight |
| Sep-26-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-30-25 | Upgrade | JP Morgan | Underweight → Neutral |
| May-22-25 | Resumed | H.C. Wainwright | Buy |
| Dec-26-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-13-24 | Downgrade | Stifel | Buy → Hold |
| Nov-11-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-14-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-10-24 | Downgrade | Barclays | Overweight → Equal Weight |
| May-10-24 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-22-24 | Downgrade | UBS | Buy → Neutral |
| Feb-21-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-21-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-21-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-20-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-16-24 | Initiated | Evercore ISI | Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Sep-14-23 | Initiated | Berenberg | Buy |
| Aug-09-23 | Initiated | Stifel | Buy |
| Jun-15-23 | Initiated | Barclays | Overweight |
| Jan-04-23 | Initiated | Guggenheim | Buy |
| Dec-01-22 | Initiated | Goldman | Buy |
| Sep-21-22 | Initiated | CapitalOne | Overweight |
| May-24-22 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-09-21 | Initiated | JP Morgan | Overweight |
| Aug-12-21 | Initiated | SVB Leerink | Outperform |
| Jun-21-21 | Initiated | Piper Sandler | Overweight |
| Jun-01-20 | Initiated | H.C. Wainwright | Buy |
| May-19-20 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-13-20 | Initiated | ROTH Capital | Buy |
| Nov-25-19 | Initiated | BMO Capital Markets | Outperform |
| Nov-25-19 | Initiated | UBS | Buy |
| Nov-25-19 | Initiated | Wells Fargo | Outperform |
View All
Rapt Therapeutics Inc Stock (RAPT) Latest News
Assessing RAPT Therapeutics (RAPT) Valuation After A Sharp Share Price Surge - Yahoo Finance
Halper Sadeh LLC Encourages NATH, RAPT, FONR Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire
Rapt Therapeutics stock hits 52-week high at $57.62 By Investing.com - Investing.com Nigeria
RAPT Stock Soars On GSK Takeover Deal Valuing Company At $2.2 Billion - Stocktwits
RAPT Therapeutics (RAPT) Receives Downgrade to Equal-Weight by B - GuruFocus
RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc.RAPT - The AI Journal
Barclays Reaffirms Equal Weight Rating for Rapt Therapeutics (NASDAQ:RAPT) - MarketBeat
GSK to Boost Respiratory & Immunology Pipeline With $2.2B RAPT Buyout - Finviz
Rapt Therapeutics stock hits 52-week high at $57.62 - Investing.com
RTW Biotech Opp.GSK to acquire RAPT Therapeutics - Research Tree
Rapt Therapeutics (RAPT) Stock: Pharma Giant GSK Pays $2.2 Billion for Biotech - Blockonomi
GSK acquires food allergy firm Rapt Therapeutics for $2.2bn - European Pharmaceutical Review
GSK acquires Rapt Therapeutics stock for $2.2 billion as Leerink downgrades - Investing.com Nigeria
GSK to buy Rapt Therapeutics in deal valued at $2.2B - MSN
GSK acquires Rapt Therapeutics stock for $2.2 billion as Leerink downgrades By Investing.com - Investing.com Canada
RTW Biotech welcomes GSK deal to buy RAPT Therapeutics - marketscreener.com
Rapt Therapeutics (NASDAQ:RAPT) Downgraded to "Hold" Rating by Clear Str - MarketBeat
Rapt Therapeutics (RAPT) Stock: GSK Snaps Up Biotech in $2.2 Billion Deal - CoinCentral
GSK enters agreement to acquire RAPT Therapeutics - marketscreener.com
UK: GSK agrees acquisition of RAPT Therapeutics in transaction valued at US$2.2bn - Investors in Healthcare
Aug Rallies: What analysts say about RAPT Therapeutics Inc stockMarket Trend Report & Scalable Portfolio Growth Ideas - baoquankhu1.vn
Halper Sadeh Investigates Calavo, RAPT, and Confluent Shareholder Rights - Intellectia AI
Halper Sadeh LLC Encourages CVGW, RAPT, CFLT Shareholders to Contact the Firm to Discuss Their Rights - marketscreener.com
GSK to buy RAPT Therapeutics for $2.2 billion - wimz.com
GSK announces $2.2 billion agreement to acquire RAPT Therapeutics By Investing.com - Investing.com Nigeria
Why Rapt Therapeutics Stock Soared Today - The Globe and Mail
GSK to Acquire RAPT Therapeutics for $2.2 Billion, Bolstering Food Allergy Pipeline - NAI500
GSK makes $2.2 billion swoop for RAPT Therapeutics' food allergy drug - ET Pharma
GSK's $2 Billion Acquisition of RAPT Therapeutics | PharmExec - PharmExec.com
RAPT Therapeutics stock jumps 64% as GSK agrees $2.2 billion takeover at $58 a share - TechStock²
Eyeing food allergy opportunity, GSK buys Rapt for $2.2B and its China asset - BioCentury
Rapt Therapeutics Acquired by GSK for $2.2 Billion, Shares Surge Over 60% - Intellectia AI
GSK gaining Rapt’s allergy drug in $2.2B M&A - BioWorld MedTech
Why Rapt Therapeutics Stock Soared Today - The Motley Fool
Piper’s Overweight Rating Boosts RAPT Stock Prospects - timothysykes.com
This Biotech Stock Surges 64%. The Big Pharma M&A Battle Is Heating Up. - Barron's
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Big drug company makes $2.2 billion play for Peninsula biopharma, food allergy drugSan Francisco Business Times - The Business Journals
GSK Digs In On Allergies With $2.2 Billion Rapt Therapeutics Buyout - Investor's Business Daily
Latham & Watkins Advises on GSK’s US$2.2 Billion Acquisition of RAPT Therapeutics - Latham & Watkins LLP
Promising Small Cap Stocks To Watch TodayJanuary 20th - MarketBeat
Top Value Stocks To ResearchJanuary 20th - MarketBeat
Lifesci Capital Reaffirms "Market Perform" Rating for Rapt Therapeutics (NASDAQ:RAPT) - MarketBeat
Rapt Therapeutics (NASDAQ:RAPT) Earns "Equal Weight" Rating from Wells Fargo & Company - MarketBeat
RAPT Therapeutics: A Buy As GSK Acquisition Highlights Long-Acting IgE Candidate (RAPT) - Seeking Alpha
Monteverde & Associates Investigates RAPT Sale to GSK, Shareholders to Receive $58 per Share - Intellectia AI
GSK Acquires Forbion's RAPT Therapeutics for $2.2 Billion - Intellectia AI
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of RAPT Therapeutics, Inc. (NASDAQ: RAPT) - PR Newswire
Forbion Announces Second Exit from Forbion Growth Fund III Following $2.2 Billion Acquisition of RAPT Therapeutics by GSK - manilatimes.net
Top Pharmaceutical Stocks To Follow NowJanuary 20th - MarketBeat
Promising Medical Stocks To Follow TodayJanuary 20th - MarketBeat
Rapt Therapeutics Inc Stock (RAPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.92%
2.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):